Abstract：Objective To understand the current status of the off-label use of neurotrophic auxiliary drugs in our hospital,analyze the possible risks of drug use,and propose corresponding solutions to provide reference for the standardized management of neuropharmacologic auxiliary drugs.Methods A total of 360 prescriptions of inpatients from January to December in 2017 in our hospital were randomly selected.Statistical results of the off-label use of neurotrophic auxiliary drugs in our hospital were summarized and analyzed referred to the latest edition of the pharmaceuticals,guidelines for the use of drugs at home and abroad,and the latest evidence-based medical evidence.Results Out of 360 prescriptions,246 prescriptions for the off-label drug use accounted for 68.3%of the total prescriptions.The most common form of the off-label drug use was hyperindicated drug use,followed by over-dosage and over-treatment drug use,respectively accounting for 82.9%,26.0%,and 23.6%of the total number of instructions.The ratio of off-label drug use,Edaravone,Oxiracetam and Flunarizine Hydrochloride Capsules respectively was 69.3%,97.6%,and 100%.In the process of off-label drug use,the highest incidence of adverse reactions was Oxiracetam Injection(27.8%),followed by Piracetam(21.4%)and Edaravone Injection(21.1%).Conclusion The clinical practice of the off-label use of neurotrophic auxiliary drugs is very common,but it has certain rationality and cannot be generalized.Clinicians should rationally use drugs on the basis of drug instructions.Pharmacy personnel should actively cooperate with relevant departments to strengthen drug supervision and regulate the behavior of the off-label drug use.
Deng KW，Shi XB，Zhao YX，et al.The effect of exogenous creatine phosphate on myocardial injury after percutaneous cor-onary intervention[J].Angiology，2015，66（2）：163-168.
京公网安备 11010502046607号